- Psyence (PSYG) has appointed Dr. Clive Ward-Able as its Medical Director
- He has more than 30 years’ experience in the pharmaceutical industry, within R&D, medical affairs, marketing, and sales
- Psyence is a public life science biotechnology company with a focus on natural psychedelics
- Psysence Group Inc. (PSYG) closed trading at C$0.085 per share
Psyence (PSYG) has appointed of Dr. Clive Ward-Able as its Medical Director, effective immediately.
He joins the medical team in Toronto and assumes the roles of Head of Research & Development (R&D) and Early Commercialization.
Dr. Clive Ward-Able has degrees in both Pharmacy and Medicine and more than 30 years’ experience in the pharmaceutical industry, within R&D, medical affairs, marketing, and sales.
Most of his experience is in the medical aspects of the commercialization of a pharmaceutical product.
Dr. Neil Maresky, CEO of Psyence commented, “We are fortunate to attract Clive as Medical Director, we are building a world class team to enhance Psyence’s R&D and commercialization capability and I believe that Clive, with his deep expertise in drug development and commercialization, is the ideal candidate for this important role. Clive joins our world-class medical team and will play an important role in our palliative care clinical trial.”
The company is designing clinical trials using natural psilocybin in the field of palliative care, focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to an incurable cancer diagnosis.
Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Psysence Group Inc. (PSYG) closed trading at C$0.085 per share.